In metabolic syndrome, the amount of bioavailable IGF1 increases via hyperglycemia-induced suppression of IGFBP synthesis and/or hyperinsulinemia-induced promotion of hepatic GH receptor expression and IGF1 synthesis (Braun et al., 2011). The gene discussed is IGF1; the disease is hyperinsulinism.